Brian F. Kiesel

TL;DR: The combination of veliparib with metronomic cyclophosphamide is well tolerated and shows promising activity in a subset of patients with BRCA mutations.

TL;DR: It is shown that the ATR kinase inhibitor AZD6738 combines with conformal radiation therapy to attenuate radiation-induced CD8+ T cell exhaustion and potentiate T cell activity in mouse models of Kras-mutant cancer.

TL;DR: Veliparib at 300 mg twice daily combined with cisplatin and vinorelbine is well tolerated with encouraging response rates, and a phase II randomized trial is planned to assess veliparIB's contribution to cisPlatin chemotherapy in metastatic TNBC and BRCA mutation–associated breast cancer.

TL;DR: Veliparib (V) (ABT-888) is a potent, oral PARP 1/2 inhibitor with preclinical and clinical efficacy in BRCA+ malignancies and there are known similarities between BRCa+ cancers.

TL;DR: Maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics (PK) of veliparib with AC and PAR levels in peripheral blood mononuclear cells (PBMCs) were determined and Objective antitumor activity was seen in BRCA mutation carriers.